COMPANY INTRODUCTION

Established in 2015, VitaVitro Biotech is a leading Chinese company specializing in high-quality support for human IVF laboratories worldwide. We are aiming to bring Advancing IVF Solutions for Tomorrow's Families. Our global operation includes our manufacturing base in Shenzhen, R&D centers in Suzhou and Dalian, and clinical partners all around the world. Our products come with full after-sales support, and we also offer a comprehensive range of IVF laboratory support services.

OUR MISSION

Advancing IVF solutions for tomorrow's families


CORE VALUES

Commitment to quality, adherence to regulations, innovation, and dedication to clients

QUALITY CERTIFICATIONS

Our company has established a quality control system for manufacturing medical devices in accordance with the requirements of multiple certifications and national regulations, including the United States (QSR820, ISO13485: 2016), Europe (93/42/EEC), and China.

Each product is carefully manufactured in facilities meeting the highest GMP sanitation standards, Each batch of products is tested strictly, conforming to **USP**, **EP**, and **ChP** guidelines. Testing includes bacterial endotoxins, sterilization, pH, and osmotic pressure.





Shenzhen VitaVitro Biotech Co., Ltd. R601, Building B, Hai Ke Xing Tech Park Pingshan, Shenzhen, Guangdong 518118

Phone: +86 (755) 84511813 Email: tech@vitavitro.com

www.vitavitro.com



VitaVitro Biotech





VITRIFICATION AND WARMING SOLUTIONS



ADVANCING IVF SOLUTIONS FOR TOMORROW'S FAMILIES

SUITABLE FOR CRYOPRESERVATION OF HUMAN MII OOCYTES OR EMBRYOS AT DIFFERENT DEVELOPMENTAL STAGES

Independent international clinical data

FROZEN EMBRYO TRANSFER CLINICAL OUTCOMES




Note: As of July 2017, this clinical trial has observed 687 frozen embryo transfers. Of these, 417 of the participants were under 35 years old, 125 participants were 35-36 years old, 65 were 37-38 years old, 40 participants were 39-40 years old, and 40 participants were over 40.

Prof. Gábor Vajta Inventor





Independent domestic clinical data

FROZEN BLASTOCYST TRANSFER CLINICAL OUTCOMES



Note: Participants in this clinical trial are aged from 20 to 38. As of June 2020, the test group consists of 93 participants, and data continues to be collected.





1-2 hours after warming









PRINCIPAL COMPONENTS

M199-Hepes buffer, dimethyl sulfoxide, ethylene glycol, sucrose, others

Antibiotic free, allergy safe

QUALITY CONTROL


	VitaVitro
Endotoxin	< 0.25 EU/mL
Mouse embryo blastocyst rate	≥ 80%
pH	7.2~7.6

ORDERING INFORMATION

Product	Product Number	Specifications
VitaVitro Vitrification Kit	V002001	HV1 1.0 ml * 1 HV2 1.0 ml * 1 HHM 1.0 ml * 1
VitaVitro Warming Kit	V003001	HW1 1.5 ml * 2 HW2 1.0 ml * 1 HHM 1.8 ml * 1

Storage: 2-8°C Shelf Life: 12 months

FREE COACHING APP







REFERENCE

- 1 Gábor Vajta. Are programmable freezers still needed in the embryo laboratory? Review on vitrification. Reproductive BioMedicine Online 2006; 12:779-796.
- 2 Gábor Vajta. Vitrification in human and domestic animal embryology: work in progress. Reproduction, Fertility and Development (2012), doi.org/10.1071/RD12118.
- 3 Gábor Vajta, Anikó Reichart, Filippo Ubaldi, Laura Rienzis. From a backup technology to a strategy-outlining approach: the success story of cryopreservation. Expert Rev. Obstet. Cyneco. 8(2), (2013).
- N. De Munck, Gá. Vajta, Safety and efficiency of oocyte vitrification, Cryobiology (2017), doi: 10.1016/j.cryobiol.2017.07.009.
- S Gábor Vajta, Vitrification in ART: past, present, and future, Theriogenology (2020), doi.org/10.1016/j.theriogenology.2020.01.057.